No-see docs are know-nothings when it comes to new drug info, study suggests

Share this article:
Vytorin Rxs to sink deeper: survey
Vytorin Rxs to sink deeper: survey
An AstraZeneca-sponsored study found that doctors who don't see sales reps are far slower to respond to medical developments such as new products, black box warnings and clinical trials data.

The study, executed by ZS Associates and a pair of ex-AstraZeneca execs, was published in The Journal of Clinical Hypertension under the title (deep breath): “Can Access Limits of Sales Representatives to Physicians Affect Clinical Prescription Decisions? A Study of Recent Events with Diabetes and Lipid Drugs.” Using ZS' annual AccessMonitor report, which tracks the frequency of rep-physician meetings from a pool of 300,000 physicians, the authors looked at prescribing habits following three events: the October, 2006 launch of Januvia; the August 2007 black box warning on Avandia; and the January, 2008 release of discouraging clinical trials data for Vytorin.

No-see docs who maintained “very low” rep access to their offices were up to 4.6 times slower to introduce Januvia to patients than were those who imposed a “medium” level of access, as determined by the authors. The “very low” access docs took four times longer to reduce their use of Avandia than their “medium” access colleagues, and showed “significantly less” response to the Vytorin data than did their less restrictive colleagues.

“Policies that promote physician ignorance of new medical information resulting from access limits runs counter to protecting patient health,” said the study's lead author George Chressanthis, a former AstraZeneca exec who is now acting director of the Center for Healthcare Research and Management at Temple University's Fox School of Business.  

Primary care docs, the study said, rely much more on reps for drug info than do specialists. “Because specialists concentrate in a narrow field, they can stay current by other means, including conferences, online forums, podcasts and academic journals,” said ZS managing principal Pratap Khedkar, who co-authored the study. “Thus, the updates they receive from reps have less impact on their prescribing abilities.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...